Trinity Health has an outpatient infusion clinic for administering REGEN-COV™ (casirivimab and imdevimab), a monoclonal antibody treatment for COVID-19. REGEN-COV™ was authorized by the United States Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA) declaration for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients who qualify for treatment. The goal of this medication is to keep patients from worsening to the point of requiring hospitalization due to COVID-19.
How to Obtain Treatment
- Please note that consent for treatment is required.
- Trinity Health patients - please call your primary care provider to request a referral for treatment.
- Non-Trinity-Health patients – please call your primary care provider.
- If you do not have a primary care provider, call Trinity Health at 701-857-DR4U (3748).
A Trinity Health provider working with the infusion clinic will review the referral form upon receipt and contact patients who qualify for REGEN-COV™ to coordinate services as soon as possible. The infusion clinic is located at Trinity Health East Ridge, 1250 21st Ave SE, Minot.
REGEN-COV™ IS NOT authorized for use in patients:
- Who are hospitalized due to COVID-19, OR
- Who require oxygen therapy due to COVID-19, OR
- Who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity
Patients interested in REGEN-COV™ should read the Fact Sheet for Patients, Parents and Caregivers and the Frequently Asked Questions below.
Frequently Asked Questions
What are monoclonal antibodies?
Antibodies are proteins that people’s bodies make to fight viruses, such as the virus that causes COVID-19. Antibodies made in a laboratory act a lot like natural antibodies to limit the amount of virus in your body. They are called monoclonal antibodies.
Monoclonal antibody treatment with REGEN-COV™ is for people who have tested positive for COVID-19 and have mild to moderate symptoms. These treatments are allowed by the U.S. Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA) while clinical studies continue to look at their usefulness and safety. For more information about EUA’s, click here: FDA Emergency Use Authorization – COVID-19 Drugs
Who can get REGEN-COV™?
REGEN-COV™ can be used by people with mild to moderate COVID-19 who:
- Are adults and pediatric patients (12 years of age and older weighing at least 40 kg, or 88 pounds)
- Have positive results of direct SARS-CoV-2 viral testing
- Are at high risk for progression to severe COVID-19, including hospitalization or death
Contact your doctor or health care provider about whether you should get treatment with REGEN-COV™.
Who is considered at high risk?
The following medical conditions or other factors may place adults and pediatric patients (age 12-17 years and weighing at least 40 kg, or 88 pounds) at higher risk for progression to severe COVID-19:
- Older age (for example, age ≥65 years of age)
- Obesity or being overweight (for example, BMI >25 kg/m2, or if age 12-17, have BMI ≥85th percentile for their age and gender based on CDC growth charts)
- Chronic kidney disease
- Immunosuppressive disease or immunosuppressive treatment
- Cardiovascular disease (including congenital heart disease) or hypertension
- Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension)
- Sickle cell disease
- Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
- Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)
Other medical conditions or factors (for example, race or ethnicity) may also place individual patients at high risk for progression to severe COVID-19 and authorization of REGEN-COV™ under the EUA is not limited to the medical conditions or factors listed above.
Does treatment work?
Though clinical trials for REGEN-COV™ are ongoing, studies have shown a decrease in hospitalizations and emergency room visits and a decrease in the amount of virus in an infected person’s blood.
What are the side effects of REGEN-COV™?
The most common reported side effects with REGEN-COV™ are nausea, diarrhea, dizziness, headache, itchiness, and vomiting. Rare severe allergic reactions have been reported in clinical studies.
Allergic reactions can happen during and after infusion with REGEN-COV™. Tell your healthcare provider right away if you get any of the following signs and symptoms of allergic reactions: fever, chills, nausea, headache, shortness of breath, low or high blood pressure, rapid or slow heart rate, chest discomfort or pain, weakness, confusion, feeling tired, wheezing, swelling of your lips, face, or throat, rash including hives, itching, muscle aches, feeling faint, dizziness and sweating. These reactions may be severe or life threatening.
Worsening symptoms after treatment: You may experience new or worsening symptoms after infusion, including fever, difficulty breathing, rapid or slow heart rate, tiredness, weakness or confusion. If these occur, contact your healthcare provider or seek immediate medical attention as some of these events have required hospitalization. It is unknown if these events are related to treatment or are due to the progression of COVID-19.
It is possible that REGEN-COV could interfere with your body’s own ability to fight off a future infection of COVID-19. Similarly, REGEN-COV may reduce your body’s immune response to a vaccine for COVID-19. Specific studies have not been conducted to address these possible risks. Talk to your healthcare provider if you have any questions.
The side effects of getting any medicine by vein may include brief pain, bleeding, bruising of the skin, soreness, swelling, and possible infection at the infusion site.
Where can I get REGEN-COV™?
Talk to your doctor or other health care professional about whether you should get treatment with REGEN-COV™. If you qualify for REGEN-COV™, you’ll be directed to the infusion clinic located at Trinity Health East Ridge, 1250 21st Ave SE, Minot, ND. The clinic accepts referrals from providers across the region both within and outside of Trinity Health.
How is REGEN-COV™ given?
REGEN-COV™ is given into a vein by intravenous (IV) infusion. Antibodies may be administered only in settings where health care providers have immediate access to medications to treat any reactions and where emergency medical systems are available, if needed.
What is the cost of REGEN-COV™?
The federal government provided states with initial supplies of REGEN-COV™. Consequently, there is no cost to patients at this time. However, some hospitals may bill insurance companies to administer the drug. More information on insurance coverage of antibody treatments can be found at CMS: Coverage of Monoclonal Antibody Products to Treat COVID-19 (PDF).
Will this affect my ability to get the COVID-19 vaccine?
We do not yet know how effective vaccines are in someone who has previously received an antibody treatment like REGEN-COV™ for a COVID-19 infection, or whether the antibody treatment could interfere with your body’s own immune response to a vaccine. Once you have had COVID-19, you are very unlikely to be reinfected for three months afterward. So, if you receive REGEN-COV™, you should delay receiving a vaccine for three months.
Helpful Resource Links
Please view the links below for additional information from North Dakota Department of Health and Regeneron Pharmaceuticals, Inc.: